Arrowhead misses the target in alpha-1 antitrypsin deficiency
The Takeda-partnered project fazirsiran shows an impressive reduction in mutant protein, but questions about fibrosis remain.
Fate runs out of excuses
The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.
Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Clinical and corporate developments over the Christmas period
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
